

LJMU Research Online

Hanson, K, Robinson, SR, Al-Yousuf, K, Hendry, AE, Sexton, DW, Sherwood, V and Wheeler, GN

The anti-rheumatic drug, leflunomide, synergizes with MEK inhibition to suppress melanoma growth

http://researchonline.ljmu.ac.uk/id/eprint/8054/

Article

Citation (please note it is advisable to refer to the publisher's version if you intend to cite from this work)

Hanson, K, Robinson, SR, Al-Yousuf, K, Hendry, AE, Sexton, DW, Sherwood, V and Wheeler, GN (2017) The anti-rheumatic drug, leflunomide, synergizes with MEK inhibition to suppress melanoma growth. Oncotarget, 9 (3). ISSN 1949-2553

LJMU has developed LJMU Research Online for users to access the research output of the University more effectively. Copyright © and Moral Rights for the papers on this site are retained by the individual authors and/or other copyright owners. Users may download and/or print one copy of any article(s) in LJMU Research Online to facilitate their private study or for non-commercial research. You may not engage in further distribution of the material or use it for any profit-making activities or any commercial gain.

The version presented here may differ from the published version or from the version of the record. Please see the repository URL above for details on accessing the published version and note that access may require a subscription.

For more information please contact researchonline@limu.ac.uk

Correction

Correction: The anti-rheumatic drug, leflunomide, synergizes with MEK inhibition to suppress melanoma growth

Kimberley Hanson¹, Stephen D. Robinson¹, Karamallah Al-Yousuf^{2,3}, Adam E. Hendry¹, Darren W. Sexton^{4,5}, Victoria Sherwood^{2,3} and Grant N. Wheeler¹

Copyright: Hanson et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License 3.0 (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

This article has been corrected: The correct Author name is given below:

Stephen D. Robinson

Original article: Oncotarget. 2018; 9:3815-3829. https://doi.org/10.18632/oncotarget.23378

¹ School of Biological Sciences, University of East Anglia, Norwich Research Park, Norwich, NR4 7TJ, UK

² School of Pharmacy, University of East Anglia, Norwich Research Park, Norwich, NR4 7TJ, UK

³ Present address: Division of Cancer Sciences, School of Medicine, Ninewells Hospital and Medical School, University of Dundee, Dundee, DD1 9SY, UK

⁴ Norwich Medical School, University of East Anglia, Norwich Research Park, Norwich, NR4 7TJ, UK

⁵ Present address: Pharmacy and Biomedical Sciences, Liverpool John Moores University, Liverpool, L3 3AF, UK **Published**: November 27, 2018